Skip to main content
SpringerLink
Log in

Oocytes Retrieval in Metabolic Syndrome

  • Chapter
  • First Online:
Pick Up and Oocyte Management

  • 705 Accesses

Abstract

Pregnancy-related cardiovascular complications are rare clinical conditions that can lead to significant maternal morbidity and mortality. With the implementation of infertility treatment, a new selected population of woman can experience pregnancy. Women with multiple medical problems and women near or beyond menopause are now able to conceive. Despite many unanswered questions, clinicians should be prepared for the challenges and potential cardiovascular complications related to patients who are epidemiologically different than those seen in the past.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cromi A, Marconi N, Casarin J, Cominotti S, Pinelli C, Riccardi M, Ghezzi F. Maternal intra and postpartum near-miss following assisted reproductive technology: a retrospective study. BJOG. 2018;125:1569–78.

    CAS  PubMed  Google Scholar 

  2. Blickstein I. Motherhood at or beyond the edge of reproductive age. Int J Fertil Womens Med. 2003;48(1):17–24.

    PubMed  Google Scholar 

  3. Hage FG, Mansur SJ, Xing D, Oparil S. Hypertension in women. Kidney Int Suppl. 2013;3:352–6.

    CAS  Google Scholar 

  4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.

    PubMed  Google Scholar 

  5. Bateman BT, Shaw KM, Kuklina EV, Callaghan WM, Seely EW, Hernández-Díaz S. Hypertension in women of reproductive age in the United States: NHANES 1999–2008. PLoS One. 2012;7(4):e36171.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369–77.

    PubMed  Google Scholar 

  7. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, et al. Risk factors for preeclampsia, abruption placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development network of maternal-fetal medicine units. N Engl J Med. 1998;339:667–71.

    CAS  PubMed  Google Scholar 

  8. Qin J, Liu X, Sheng X, Wang H, Gao S. Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: a meta-analysis of cohort studies. Fertil Steril. 2016;105(1):73–85.

    PubMed  Google Scholar 

  9. Jackson S, Hong C, Wang ET, Alexander C, Gregory KD, Pisarska MD. Pregnancy outcomes in very advanced maternal age pregnancies: the impact of assisted reproductive technology. Fertil Steril. 2015;103(1):76–80.

    PubMed  Google Scholar 

  10. Holst S, Kjær SK, Jørgensen ME, Damm P, Jensen A. Fertility problems and risk of gestational diabetes mellitus: a nationwide cohort study. Fertil Steril. 2016;106(2):427–34.

    PubMed  Google Scholar 

  11. Wang YA, Nikravan R, Smith HC, Sullivan EA. Higher prevalence of gestational diabetes mellitus following assisted reproduction technology treatment. Hum Reprod. 2013;28(9):2554–61.

    CAS  PubMed  Google Scholar 

  12. Bashmakova NV, Davydenko NB, Malgina GB, Putilova NV. Epidemiology of critical states during pregnancy after assisted reproductive technologies. Gynecol Endocrinol. 2016;32(sup2):47–51.

    CAS  PubMed  Google Scholar 

  13. Barua S, Hng TM, Smith H, Bradford J, McLean M. Ovulatory disorders are an independent risk factor for pregnancy complications in women receiving assisted reproduction treatments. Aust N Z J Obstet Gynaecol. 2017;57(3):286–93.

    PubMed  Google Scholar 

  14. Stern JE, Luke B, Tobias M, Gopal D, Hornstein MD, Diop H. Adverse pregnancy and birth outcomes associated with underlying diagnosis with and without assisted reproductive technology treatment. Fertil Steril. 2015;103(6):1438–45.

    PubMed  PubMed Central  Google Scholar 

  15. Ashrafi M, Gosili R, Hosseini R, Arabipoor A, Ahmadi J, Chehrazi M. Risk of gestational diabetes mellitus in patients undergoing assisted reproductive techniques. Eur J Obstet Gynecol Reprod Biol. 2014;176:149–52.

    CAS  PubMed  Google Scholar 

  16. Carbillon L, Gronier H, Cedrin-Durnerin I, Pharisien I, Nguyen MT, Valensi P, Cosson E. The impact of ovulation induction and ovarian stimulation on the risk of pregnancy-induced hypertension and on neonatal outcomes: a case/control study. Eur J Obstet Gynecol Reprod Biol. 2017;217:137–43.

    CAS  PubMed  Google Scholar 

  17. Chaveeva P, Carbone IF, Syngelaki A, Akolekar R, Nicolaides KH. Contribution of method of conception on pregnancy outcome after the 11–13 weeks scan. Fetal Diagn Ther. 2011;30:9–22.

    PubMed  Google Scholar 

  18. Jie Z, Yiling D, Ling Y. Association of assisted reproductive technology with adverse pregnancy outcomes. Iran J Reprod Med. 2015;13(3):169–80.

    PubMed  PubMed Central  Google Scholar 

  19. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol. 1999;4(2):311–5.

    Google Scholar 

  20. Tidswell M. Peripartum cardiomyopathy. Crit Care Clin. 2004;20:777–88.

    PubMed  Google Scholar 

  21. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35(3):701–5.

    CAS  PubMed  Google Scholar 

  22. Pearson G, Veille J, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283(9):1183–8.

    CAS  PubMed  Google Scholar 

  23. Asad ZUA, Maiwand M, Farah F, Dasari TW. Peripartum cardiomyopathy: a systematic review of the literature. Clin Cardiol. 2018;41(5):693–7.

    PubMed  PubMed Central  Google Scholar 

  24. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62(18):1715–23.

    PubMed  PubMed Central  Google Scholar 

  25. Shani H, Kuperstein R, Berlin A, Arad M, Goldenberg I, Simchen MJ. Peripartum cardiomyopathy—risk factors, characteristics and long-term follow-up. J Perinat Med. 2015;43(1):95–101.

    PubMed  Google Scholar 

  26. Zhang J, Lai Z, Shi L, Tian Y, Luo A, Xu Z, Ma X, Wang S. Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice. Aging (Albany NY). 2018;10(5):1089–102.

    CAS  Google Scholar 

  27. Binder H, Dittrich R, Einhaus F, Krieg J, Müller A, Strauss R, Beckmann MW, Cupisti S. Update on ovarian hyperstimulation syndrome: part 1—incidence and pathogenesis. Int J Fertil Womens Med. 2007;52(1):11–26.

    CAS  PubMed  Google Scholar 

  28. Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. Tex Heart Inst J. 2012;39(1):8–16.

    PubMed  PubMed Central  Google Scholar 

  29. Williams J, Mozurkewich E, Chilimigras J, Van De Ven C. Critical care in obstetrics: pregnancy specific conditions. Best Pract Res Clin Obstet Gynaecol. 2008;22(5):825–46.

    PubMed  Google Scholar 

  30. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12(1):10–38.

    Google Scholar 

  31. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol. 1992;168(2):493–5.

    Google Scholar 

  32. Egan DJ, Bisanzo MC, Hutson HR. Emergency department evaluation and management of peripartum cardiomyopathy. J Emerg Med. 2009;36(2):141–7.

    PubMed  Google Scholar 

  33. Moioli M, Menada MV, Bentivoglio G, Ferrero S. Peripartum cardiomyopathy. Arch Gynecol Obstet. 2010;281(2):183–8.

    PubMed  Google Scholar 

  34. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al.; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–778.

    Google Scholar 

  35. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J. 2011;87(1023):34–9.

    PubMed  Google Scholar 

  36. Ro A, Frishman W. Peripartum cardiomyopathy. Cardiol Rev. 2006;14(1):35–42.

    PubMed  Google Scholar 

  37. Lata I, Gupta R, Sahu S, Singh H. Emergency management of decompensated peripartum cardiomyopathy. J Emerg Trauma Shock. 2009;2(2):124–8.

    PubMed  PubMed Central  Google Scholar 

  38. Arnold JM, Liu P, Demers C, et al.; Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendation on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22(1):23–45.

    Google Scholar 

  39. Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy—a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol. 2008;199(4):e5–6.

    PubMed  Google Scholar 

  40. De Jong JS, Rietveld K, van Lochem LT, Bouma BJ. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur J Heart Fail. 2009;1(2):220–2.

    Google Scholar 

  41. Gavaert S, van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and “bridge to” therapeutic options: a single center experience with intra-aortic balloon pump, extracorporeal membrane oxygenation and continuous flow left ventricular assist devices. Crit Care. 2011;15(2):R93.

    Google Scholar 

  42. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118(3):295–303.

    PubMed  Google Scholar 

  43. Keogh A, Macdonald P, Spratt P, Marshman D, Larbalestier R, Kaan A. Outcome in peripartum cardiomyopathy after heart transplantation. J Heart Lung Transplant. 1994;13(2):202–7.

    CAS  PubMed  Google Scholar 

  44. Smith IJ, Gillham MJ. Fulminant peripartum cardiomyopathy rescue with extracorporeal membranous oxygenation. Int J Obstet Anesth. 2009;18(2):186–8.

    CAS  PubMed  Google Scholar 

  45. Udell JA, Lu H, Redelmeier DA. Failure of fertility therapy and subsequent adverse cardiovascular events. CMAJ. 2017;189:E391–7.

    PubMed  PubMed Central  Google Scholar 

  46. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104:515–21.

    CAS  PubMed  Google Scholar 

  47. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31:2124–32.

    PubMed  Google Scholar 

  48. Lam W. Heart disease and pregnancy. Tex Heart Inst J. 2012;39(2):237–9.

    PubMed  PubMed Central  Google Scholar 

  49. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008;52(3):171–80.

    PubMed  Google Scholar 

  50. Dayan N, Laskin CA, Spitzer K, et al. Pregnancy complications in women with heart disease conceiving with fertility therapy. J Am Coll Cardiol. 2014;64(17):1862–4.

    PubMed  Google Scholar 

  51. Sazonova A, Redelmeier DA. Long term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol. 2013;62:1704–12.

    Google Scholar 

  52. De Viti D, et al. Congenital aorto-right ventricular fistula associated with pulmonary hypertension in an old female patient. J Cardiovasc Echogr. 2018;28(2):141–2.

    PubMed  PubMed Central  Google Scholar 

  53. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–82.

    CAS  PubMed  Google Scholar 

  54. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.

    CAS  PubMed  Google Scholar 

  55. Vignesh JP, Mohan V. Polycystic ovary syndrome: a component of metabolic syndrome? J Postgrad Med. 2007;53:128–34.

    CAS  PubMed  Google Scholar 

  56. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.

    Google Scholar 

  57. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–36.

    PubMed  PubMed Central  Google Scholar 

  58. Alvarez Cosmea A, López Fernández V, Suárez García S, Arias García T, Prieto Díaz MA, Díaz González L. Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions. Med Clin (Barc). 2005;124:368–70.

    Google Scholar 

  59. Seidell JC. Obesity, insulin resistance and diabetes—a worldwide epidemic. Br J Nutr. 2000;83(Suppl 1):S5–8.

    CAS  PubMed  Google Scholar 

  60. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132:989–93.

    CAS  PubMed  Google Scholar 

  61. Sharma S, Majumdar A. Prevalence of metabolic syndrome in relation to body mass index and polycystic ovarian syndrome in Indian women. J Hum Reprod Sci. 2015;8(4):202–8.

    PubMed  PubMed Central  Google Scholar 

  62. Madani T, Hosseini R, Ramezanali F, Khalili G, et al. Metabolic syndrome in infertile women with polycystic ovarian syndrome. Arch Endocrinol Metab. 2016;60(3):199–204.

    PubMed  Google Scholar 

  63. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52(7):908–15.

    CAS  PubMed  Google Scholar 

  64. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929–35.

    CAS  PubMed  Google Scholar 

  65. Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol. 2010;26(7):516–20.

    PubMed  Google Scholar 

  66. Weerakiet S, Bunnag P, Phakdeekitcharoen B, Wansumrith S, Chanprasertyothin S, Jultanmas R, et al. Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. Gynecol Endocrinol. 2007;23(3):153–60.

    PubMed  Google Scholar 

  67. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril. 2008;89(3):649–55.

    PubMed  Google Scholar 

  68. Ni RM, Mo Y, Chen X, Zhong J, Liu W, Yang D. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161(3):411–8.

    CAS  PubMed  Google Scholar 

  69. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract. 2007;77(Suppl 1):S243–6.

    CAS  PubMed  Google Scholar 

  70. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod. 2005;20(9):2409–13.

    PubMed  Google Scholar 

  71. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154(1):141–5.

    CAS  PubMed  Google Scholar 

  72. Bilal M, Haseeb A, Rehman A. Relationship of polycystic ovarian syndrome with cardiovascular risk factors. Diabetes Metab Syndr. 2018;12(3):375–80.

    PubMed  Google Scholar 

  73. Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. 2004;56(1):27–39.

    CAS  PubMed  Google Scholar 

  74. Sukalich S, Guzick D. Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med. 2003;21(3):309–15.

    PubMed  Google Scholar 

  75. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol. 2008;60(1):39–51.

    CAS  PubMed  Google Scholar 

  76. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106(1):131–7.

    PubMed  Google Scholar 

  77. Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med. 2010;27(5):498–515.

    CAS  PubMed  Google Scholar 

  78. Talbott EO, Zborowskii JV, et al. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. 2004;56(1):27–39.

    CAS  PubMed  Google Scholar 

  79. Glintborg D, Rubin KH, et al. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17(1):37.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Laird SM, Tuckerman EM, Li TC. Cytokine expression in the endometrium of women with implantation failure and recurrent miscarriage. Reprod Biomed Online. 2006;13(1):13–23.

    CAS  PubMed  Google Scholar 

  81. Marciniak A, Nawrocka Rutkowska J, et al. Cardiovascular system disease in patient with polycystic ovary syndrome—the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 2016;23(4):537–41.

    CAS  PubMed  Google Scholar 

  82. Dawood A, Alkafrawy N, et al. The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(4):294–7.

    CAS  PubMed  Google Scholar 

  83. Kaya C, Pabuccu R, et al. Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertil Steril. 2010;93(4):1200–7.

    CAS  PubMed  Google Scholar 

  84. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112–26.

    PubMed  Google Scholar 

  85. Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2015;191:15–22.

    CAS  PubMed  Google Scholar 

  86. Krishna MB, Joseph A, et al. Impaired arginine metabolism coupled to a defective redox conduit contributes to low plasma nitric oxide in polycystic ovary syndrome. Cell Physiol Biochem. 2017;43(5):1880–92.

    CAS  PubMed  Google Scholar 

  87. Kaya C, Erkan AF, Cengiz SD, Dünder I, Demirel OE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril. 2009;92(4):1372–7.

    CAS  PubMed  Google Scholar 

  88. Ozturk M, Oktem M, et al. Elevated PAPP-A levels in lean patient with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2018;57(3):394–8.

    PubMed  Google Scholar 

  89. Bonaca MP, Scirica BM, et al. Prospective evaluation of pregnancy-associated plasma proteina and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012;60(4):332–8.

    CAS  PubMed  Google Scholar 

  90. Bondagji NS. Ischaemic heart disease in pregnancy. J Saudi Heart Assoc. 2012;24(2):89–97.

    PubMed  PubMed Central  Google Scholar 

  91. Roth A, et al. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008;52(3):171–80.

    PubMed  Google Scholar 

  92. Havakuk O, Goland S, Mehra A, Elkayam U. Pregnancy and the risk of spontaneous coronary artery dissection: an analysis of 120 contemporary cases. Circ Cardiovasc Interv. 2017;10(3).

    Google Scholar 

  93. Karadag B, Roffi M. Postpartal dissection of all coronary arteries in an in vitro-fertilized postmenopausal woman. Tex Heart Inst J. 2009;36(2):168–70.

    PubMed  PubMed Central  Google Scholar 

  94. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: important underrecognised cardiometabolic risk factor in reproductive-age women. Int J Endocrinol. 2015;2015:786362.

    PubMed  PubMed Central  Google Scholar 

  96. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–88.

    CAS  PubMed  Google Scholar 

  98. Kauffman RP, Baker TE, et al. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol. 2008;198(6):670.

    PubMed  Google Scholar 

  99. Daskalopoulos GN, Karkanaki A, Karagiannis A, Mikhailidis DP, Athyros VG. Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome? Angiology. 2011;62(4):285–90.

    PubMed  Google Scholar 

  100. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33(5):812–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Baldani DP, Skrgatic L, Goldstajn MS, Vrcic H, Canic T, Strelec M. Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population. Coll Antropol. 2013;37(2):465–70.

    PubMed  Google Scholar 

  102. Ciepiela P, Baczkowski T, Brelik P, et al. Biotechnological and clinical outcome of in vitro fertilization in non-obese patients with polycystic ovarian syndrome. Folia Histochem Cytobiol. 2007;45(Suppl 1):s65–71.

    PubMed  Google Scholar 

  103. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16(9):1995–8.

    CAS  PubMed  Google Scholar 

  104. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–6.

    CAS  PubMed  Google Scholar 

  105. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metab Clin Exp. 1999;48(4):437–41.

    CAS  PubMed  Google Scholar 

  106. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers. 2009;26(4):163–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048.

    CAS  PubMed  Google Scholar 

  108. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–13.

    CAS  PubMed  Google Scholar 

  109. Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol. 1990;33(1):119–31.

    CAS  Google Scholar 

  110. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998;51(5):415–22.

    CAS  PubMed  Google Scholar 

  111. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3):1073.

    CAS  PubMed  Google Scholar 

  112. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87(5):2013–7.

    CAS  PubMed  Google Scholar 

  113. de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(4):495–500.

    PubMed  Google Scholar 

  114. Otto-Buczkowska E, et al. Early metabolic abnormalities-insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome. Przegl Lek. 2006;63(4):234–8.

    PubMed  Google Scholar 

  115. Tsikouras P, Spyros L, et al. Features of polycystic ovary syndrome in adolescence. J Med Life. 2015;8(3):291–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increased androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91(2):492–7.

    CAS  PubMed  Google Scholar 

  117. Aydin Y, Hassa H, et al. What is the risk of metabolic syndrome in adolescents with normal BMI who have polycystic ovary syndrome? J Pediatr Adolesc Gynecol. 2015;28(4):271–4.

    PubMed  Google Scholar 

  118. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med. 2009;10(2):83–90.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Santa Maria Hospital, GVM Care and Research, Bari, Italy

    Daniele De Viti

  2. Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari, Bari, Italy

    Assunta Stragapede

  3. Ophthalmology Section the Department of Sense Organs, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy

    Elena Pacella

  4. Center for Medically Assisted Procreation, MOMO’ fertiLIFE, Bisceglie, Italy

    Domenico Baldini

Authors
  1. Daniele De Viti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Assunta Stragapede
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Pacella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Domenico Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Santa Maria Hospital, GVM Care and Research, Bari, Italy

    Antonio Malvasi

  2. Center of Medically Assisted Procreation, MOMO’ fertiLIFE Srl, Bisceglie, Italy

    Domenico Baldini

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Viti, D., Stragapede, A., Pacella, E., Baldini, D. (2020). Oocytes Retrieval in Metabolic Syndrome. In: Malvasi, A., Baldini, D. (eds) Pick Up and Oocyte Management. Springer, Cham. https://doi.org/10.1007/978-3-030-28741-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28741-2_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28740-5

  • Online ISBN: 978-3-030-28741-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation